Lukasz Kuzma/LinkedIn
Feb 16, 2026, 14:44
Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES
Lukasz Kuzma, Research Professor at University of Liverpool, shared a post on X about a recent article he and his colleague co-authored, adding:
“In our NEJM editorial with ESC Stroke Chair, we highlight the first RCT in AF more than 1 year after DES showing that NOAC monotherapy was not noninferior and statistically superior to NOAC plus clopidogrel for net adverse clinical events also with less bleeding.”
Title: Thromboprophylaxis for Atrial Fibrillation in Patients with Drug-Eluting Stents
Authors: Gregory Y.H. Lip and Lukasz Kuzma
Read the Full Article on The New England Journal of Medicine.
Stay updated with Hemostasis Today.
-
Jul 12, 2026, 16:15Louise St. Germain Bannon: Global Collaboration Is Key to Turning Scientific Innovation Into Better Care
-
Jul 12, 2026, 16:10Marc Carrier: Major Scientific Highlight Confirms the Safety of the YEARS Algorithm at ISTH 2026
-
Jul 12, 2026, 16:01Joseph R. Shaw: Sharing New Insights into Antithrombotic Therapy and Thrombin Generation at ISTH 2026
-
Jul 12, 2026, 15:45Nathan Connell: Key Clinical Advances in Heavy Menstrual Bleeding and Postpartum Hemorrhage from ISTH 2026
-
Jul 12, 2026, 15:40Anne-Claire Duchez: Join Us at ISTH 2026 to Discover Our Latest Research and Meet the Team
-
Jul 12, 2026, 12:30Reduced-Dose DOACs in GI Malignancies: Toward Personalized Anticoagulation
-
Jul 12, 2026, 08:50Where the Hemophilia Community Comes Together at ISTH 2026 – EAHAD
-
Jul 12, 2026, 08:2210 Posts Not To Miss from ISTH 2026, Part 1
-
Jul 12, 2026, 07:58Brian O Mahony: Could NXT-007 Minimize the Need for Perioperative FVIII